Use of Novoseven for arsenic trioxide-induced bleeding in PML.
Alimoghaddam
Kamran
K
Ghavamzadeh
Ardeshir
A
Jahani
Mohamad
M
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005167:Factor VII / Q000627:therapeutic use*; D015942:Factor VIIa; D006470:Hemorrhage / Q000139:chemically induced / Q000188:drug therapy*; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D008171:Lung Diseases / Q000139:chemically induced / Q000188:drug therapy*; D010087:Oxides / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa; D000077237:Arsenic Trioxide